Targeting the cholinergic anti-inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study

Joseph Magagnoli; Tammy H Cummings; James W Hardin; Jayakrishna Ambati; S Scott Sutton

doi:10.1111/dom.16060

Targeting the cholinergic anti-inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study

Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16060. Online ahead of print.

Authors

Joseph Magagnoli^{1

2}, Tammy H Cummings^{1

2}, James W Hardin^{1

3}, Jayakrishna Ambati^{4

5

6

7}, S Scott Sutton^{1

2}

Affiliations

¹ Dorn Research Institute, Columbia VA Health Care System, Columbia, South Carolina, USA.
² Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
³ Department of Epidemiology & Biostatistics, University of South Carolina, Columbia, South Carolina, USA.
⁴ Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
⁵ Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
⁶ Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
⁷ Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

PMID: 39529444
DOI: 10.1111/dom.16060

Abstract

Background: Chronic inflammation is a key factor in type 2 diabetes mellitus (T2DM) development. The cholinergic anti-inflammatory pathway (CAP) reduces inflammation by activating α7 nicotinic acetylcholine receptors (α7nAChRs) on macrophages, suppressing proinflammatory cytokines. Acetylcholinesterase inhibitors (AChEis), primarily used for Alzheimer's disease (AD), may exert anti-inflammatory effects through the CAP. One AChEi, galantamine, also directly agonizes α7nAChRs, potentially enhancing its anti-inflammatory properties.

Objective: This study aimed to investigate the association between AChEi use, particularly galantamine, and T2DM risk in AD patients.

Methods: We conducted a retrospective analysis of Veterans Health Administration (VA) data, examining early- and late-onset AD patients receiving galantamine or other AD medications. Propensity score matching was used to balance groups and minimize confounding. Cox proportional hazard models assessed T2DM risk for galantamine, other AChEis and memantine.

Results: A total of 40 065 AD patients were included in the study. Among early-onset AD patients, galantamine use significantly reduced T2DM risk (hazard ratio [HR] = 0.80, 95% confidence interval [CI]: 0.66-0.98). Memantine also showed a protective effect (HR = 0.82, 95% CI: 0.69-1) in this group. Neither galantamine nor memantine influenced T2DM risk in late-onset AD. Other AD medications showed no association with T2DM risk.

Conclusion: Galantamine use was associated with a lower risk of T2DM in early-onset AD patients, potentially due to enhanced anti-inflammatory effects through both AChE inhibition and direct α7nAChR agonism. Memantine also demonstrated a protective effect. These findings suggest potential new applications for existing AD medications in T2DM prevention, particularly in early-onset AD patients. Further research, including randomized controlled trials with diverse populations, is needed to confirm these results and the underlying mechanisms.

Keywords: database research; effectiveness; pharmacoepidemiology; type 2 diabetes.

Abstract

Grants and funding